Leukocyte Adhesion Deficiency Management Market Report 2026

Leukocyte Adhesion Deficiency Management Market Overview

• Leukocyte Adhesion Deficiency Management market size has reached to $8.59 billion in 2025 • Expected to grow to $12.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency. • Market Trend: Advancements In Leukocyte Adhesion Deficiency Management Lentiviral Vector-Based Gene Therapy Shows Promising Results • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leukocyte Adhesion Deficiency Management Market?

Leukocyte adhesion deficiency (LAD) is a rare genetic disorder affecting the immune system's ability to fight infections. It is characterized by a defect in the adhesion (stickiness) of white blood cells, specifically neutrophils, essential for the body's defense against bacteria and fungi. Management of leukocyte adhesion deficiency typically involves a multidisciplinary approach and focuses on preventing and treating infections and addressing the underlying immune system dysfunction. The main types of treatment in leukocyte adhesion deficiency management are hematopoietic stem cell transplantation, recombinant human interferon-gamma treatment, prophylactic immunoglobulin therapy, antimicrobial therapy, prophylactic therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation refers to a medical procedure where stem cells from the bone marrow or blood are transplanted into a patient to replace damaged or diseased blood-forming cells. Treatment and diagnostics such as blood tests, genetic testing, biopsies, and others are provided by end users such as hospitals, specialty clinics, and others.

What Is The Leukocyte Adhesion Deficiency Management Market Growth Forecast?

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $12.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in stem cell transplantation techniques, increasing availability of genetic testing, rising investment in rare disease research, growing adoption of personalized immunotherapy, expansion of specialized immunology care centers. Major trends in the forecast period include expansion of hematopoietic stem cell transplantation, rising adoption of gene-based diagnostic testing, growing use of prophylactic immunoglobulin therapy, increasing focus on early infection prevention, advancements in targeted immunomodulatory treatments.

Global Leukocyte Adhesion Deficiency Management Market Segmentation

1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation 2) By Diagnosis: Blood Test, Genetic Testing 3) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant, Unrelated Donor Transplant 2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing, Customized Dosing 3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) 4) By Antimicrobial Therapy: Antibiotics, Antifungal Treatments 5) By Prophylactic Therapy: Vaccination Strategies, Infection Prevention Protocols 6) By Fucose Supplementation: Oral Supplements, Intravenous Supplements

What Is The Driver Of The Leukocyte Adhesion Deficiency Management Market?

The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body's immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management industry.

Key Players In The Global Leukocyte Adhesion Deficiency Management Market

Major companies operating in the leukocyte adhesion deficiency management market are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

Global Leukocyte Adhesion Deficiency Management Market Trends and Insights

Major companies operating in the leukocyte adhesion deficiency management market are developing lentiviral vector-based gene therapy technology to improve targeted treatments and enhance patient outcomes. Lentiviral vector-based gene therapy offers a targeted approach in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune function. For instance, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, launched kresladi (marnetegragene autotemcel) for treating severe leukocyte adhesion deficiency-I (LAD-I). In a Phase 1/2 study, it achieved 100% survival at 12 months, significantly reducing infections and improving symptoms. Kresladi offers a groundbreaking option in the LAD management market, addressing critical unmet needs.

What Are Latest Mergers And Acquisitions In The Leukocyte Adhesion Deficiency Management Market?

In February 2023, Jeffrey Modell Foundation (JMF), a US-based nonprofit company for primary immunodeficiency, collaborated with Veritas Intercontinental to advance genome and exome sequencing for immunological disorders. The collaboration aims to enhance precise diagnosis and treatment by globally identifying gene abnormalities in primary immunodeficiency, such as leukocyte adhesion deficiency. Veritas Intercontinental is a Spain-based healthcare solutions company specializing in genome sequencing and analytic services.

Regional Outlook

North America was the largest region in the leukocyte adhesion deficiency management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Leukocyte Adhesion Deficiency Management Market?

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukocyte Adhesion Deficiency Management Market Report 2026?

The leukocyte adhesion deficiency management market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.